Your browser doesn't support javascript.
loading
Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial.
Wong, Mandy Oi Man; Lai, Isabel Sw; Chan, Poemen Puiman; Chan, Noel Cy; Chan, Alison Yy; Lai, Gilda Wk; Chiu, Vivian Sm; Leung, Christopher Kai-Shun.
Afiliación
  • Wong MOM; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Lai IS; Department of Ophthalmology, Hong Kong Eye Hospital, Kowloon City, Hong Kong.
  • Chan PP; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Chan NC; Department of Ophthalmology, Hong Kong Eye Hospital, Kowloon City, Hong Kong.
  • Chan AY; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Lai GW; Department of Ophthalmology, Hong Kong Eye Hospital, Kowloon City, Hong Kong.
  • Chiu VS; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Leung CK; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, Shatin, Hong Kong.
Br J Ophthalmol ; 105(4): 514-520, 2021 04.
Article en En | MEDLINE | ID: mdl-32606078
AIMS: To compare the intraocular pressure (IOP) lowering effect and safety profile between pattern scanning laser trabeculoplasty (PSLT) and selective laser trabeculoplasty (SLT) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) over a 12-month follow-up. METHODS: 132 patients with POAG or OHT were consecutively enrolled and randomised (1:1) to receive PSLT (n=65) or SLT (n=67) in a single centre. IOP was measured before and then on 1 day, 1 week, 1, 3, 6, 9 and 12 months after PSLT/SLT. The primary outcome measure was the proportion of patients with ≥20% IOP reduction at 12 months without IOP-lowering medications (complete success). RESULTS: The mean baseline IOP was 21.2±4.1 mm Hg for eyes randomised to PSLT and 21.3±4.7 mm Hg for eyes randomised to SLT (p=0.898). At 12 months, the IOP was 18.3±3.1 and 17.8±3.4 mm Hg, respectively (p=0.402). IOP measurements were comparable between the groups over 12 months (overall mean difference 0.4 mm Hg, 95% CI: -0.5 to 1.3 mm Hg). 15.4% of PSLT-treated and 25.4% of SLT-treated patients achieved treatment success (difference: 10.0%, 95% CI: -3.6 to 23.6) (p=0.155), respectively. A higher baseline IOP and a greater percentage of IOP reduction at day 1 were associated with a greater percentage of IOP reduction at 12 months (p<0.001). There were no significant differences in visual field mean deviation, average retinal nerve fibre layer thickness, corneal endothelial cell count and visual acuity between the treatment groups at the baseline and 12-month follow-up (p≥0.062). CONCLUSIONS: PSLT was not superior to SLT in terms of safety and IOP-lowering efficacy in patients with POAG or OHT. TRIAL REGISTRATION NUMBER: The clinical trial was registered in the Centre for Research and Biostatistics Clinical Trials Registry, the Chinese University of Hong Kong (Identifier CUHK_CCT00407). The full trial protocol can be accessed from the authors on request.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trabeculectomía / Agudeza Visual / Glaucoma de Ángulo Abierto / Hipertensión Ocular / Terapia por Láser / Láseres de Estado Sólido / Presión Intraocular Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Br J Ophthalmol Año: 2021 Tipo del documento: Article País de afiliación: Hong Kong

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trabeculectomía / Agudeza Visual / Glaucoma de Ángulo Abierto / Hipertensión Ocular / Terapia por Láser / Láseres de Estado Sólido / Presión Intraocular Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Br J Ophthalmol Año: 2021 Tipo del documento: Article País de afiliación: Hong Kong